ID resigns over future conflict, new ID appointed, existing ID re-appointed
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma's board on Jun 15, 2026 approved three changes: (1) re-appointed Mr. Udo J. Vetter as Independent Director for a 2nd 5-year term (Jul 21, 2026–Jul 20, 2031); (2) appointed Mr. William Robert Keller, currently ID at Wuxi Biologics, as Additional Non-Executive Independent Director; (3) accepted resignation of Mr. C.S.N. Murthy (ID) citing a potential future conflict of interest — his other company, where he is Promoter and Director, plans to enter a segment overlapping with Gland Pharma's planned activities. Board committees were realigned.
Proactive conflict-of-interest exit is a positive governance signal. New appointee adds global pharma/China expertise. Overall neutral for shareholders.